ASM Global’s Asia Pacific Presence Expands With Announcement of Strategic Partnership With Malaysian Government for Kuala Lumpur Sports City Management
ASM Global, the world’s leading venue management company and producer of live experiences, has partnered with the Malaysian Ministry of Youth and Sports via Perbadanan Stadium Malaysia (PSM) to enhance existing operations and event activity at the Kuala Lumpur Sports City precinct, the largest sports complex in the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005375/en/
Malaysia National Stadium in Kuala Lumpur Sports City (Photo: Business Wire)
The announcement is a further step forward in the Malaysian government’s ambition to see the National Sports Precinct at Bukit Jalil develop a world-class reputation as the host of leading sports, entertainment and community events. It also expands ASM Global’s footprint in Asia with the addition of an iconic sports and events precinct, including the 87,400-seat Malaysia National Stadium.
The Malaysia National Stadium is not only the largest stadium in Asia outside North Korea, it is now the largest stadium in ASM Global’s worldwide collection.
ASM Global brings its vast industry experience in redefining the guest journey, implementing the latest technology, elevating F&B offerings, and the advantage of a regionally based team together with its commercial venue know-how, wide ranging event network and technical capabilities.
ASM Global President and CEO Ron Bension said, “We’re on a robust growth curve in this part of the world. The Kuala Lumpur Sports City precinct is representative of the types of projects we’re championing that significantly enrich the venue benefits and utilize our vast international expertise and best practices.”
Chairman and Chief Executive of ASM Global Asia Pacific and Gulf Region Harvey Lister AM said the group was delighted to be partnering with the management team at the iconic Kuala Lumpur Sports City in a joint endeavor to further establish the precinct as a vibrant community and event hub for the people of Malaysia.
“We firmly believe the Malaysia National Stadium and the Axiata Arena have the potential expressed by the Malaysia Sports Ministry, and we are proud to welcome the local teams and venues into our network of venues and support the precinct in helping deliver more events for the people of Malaysia and the region,” said Lister.
ASM Global will partner with local Malaysian company Sportswork Sdn Bhd in delivering services for Kuala Lumpur Sports City.
Malaysia Sports Minister, Y.B. Dato’ Seri Ahmad Faizal bin Dato’ Azumu, said, “We see this MOU as a great opportunity for PSM and ASM Global to enhance Kuala Lumpur Sports City to a premier destination in the global sports and event industry. Both National Stadium Bukit Jalil and Axiata Arena are iconic properties owned by the Malaysian people, and we owe them a responsibility to ensure these venues make us proud.”
ABOUT ASM GLOBAL
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Follow us on Facebook, Instagram, LinkedIn and Twitter. asmglobal.com
ASM Global’s expanding family of facilities in the Asia Pacific includes the following venues:
- Entertainment and Sports Arenas: Qudos Bank Arena, Sydney; RAC Arena, Perth; Brisbane Entertainment Centre; Newcastle Entertainment Centre; Aware Super Theatre at ICC Sydney; BCEC Great Hall, Brisbane; Cairns Arena: Bangkok Arena and EM Live Theatre, Bangkok (under development), Coca Cola Arena, Dubai; Kai Tak Indoor Arena, Hong Kong; and Jeddah Arena, Saudi Arabia (under development).
- Live Performance Theatres: Brisbane, Cairns, Darwin, Sydney, Kuala Lumpur and Bahrain.
- Convention and Exhibition Centres: Brisbane, Cairns, Darwin, Newcastle, Sydney, Christchurch, Kuala Lumpur, Shenzhen, Bahrain (under construction) and Jeddah (under development).
- Stadiums: Suncorp Stadium in Brisbane; Kai Tak Sports Park, Hong Kong (under construction); a significant ownership of VenuesLive, the operator of Stadium Australia, Sydney; CommBank Stadium, Parramatta; Optus Stadium, Perth, and service provider to WIN Stadium, Wollongong; McDonald Jones Stadium, Newcastle; Netstrata Jubilee Stadium, Sydney; and Central Coast Stadium, Gosford.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
(breakwhitelight for ASM Global)
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi
Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis18.8.2022 18:27:00 CEST | Press release
Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.” The r
Aero Secures $65M in Series B Financing to Accelerate the Future of Premium Air Travel18.8.2022 18:00:00 CEST | Press release
Aero Technologies, Inc. the next-generation premium air travel company, which serves routes in both the US and Europe, today announced a $65M capital raise, $50M in Series B funding and $15M in convertible notes, for a total post-money valuation of $300M. The funding round was co-led by AlbaCore Capital Group, one of Europe’s leading alternative investment firms, and returning investors Expa and Keyframe Capital, with new investment from Capital One Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005095/en/ (Photo: Business Wire) Inspired by the golden age of aviation and designed for modern life, Aero is redefining semi-private air travel. Aero serves premium leisure travelers through private terminals, enriching the experience with personalized Concierge services - from booking to touchdown. With its fleet of sleek, black planes, Aero offers elevated, effortless guest experiences to curated destinations with
Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies18.8.2022 15:49:00 CEST | Press release
Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing. “Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom